UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017180
Receipt number R000019934
Scientific Title The effects of Teneligliptin on endothelial function in type 2 diabetes mellitus with chronic kidney disease
Date of disclosure of the study information 2015/04/20
Last modified on 2016/05/23 15:09:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effects of Teneligliptin on endothelial function in type 2 diabetes mellitus with chronic kidney disease

Acronym

Effects of Teneligliptin on endothelial function

Scientific Title

The effects of Teneligliptin on endothelial function in type 2 diabetes mellitus with chronic kidney disease

Scientific Title:Acronym

Effects of Teneligliptin on endothelial function

Region

Japan


Condition

Condition

Type 2 diabetes mellitus with chronic kidney disease

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate whether teneligliptin improve endothelial function, and decrease production of oxidative stress.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The changes in endothelial function and oxidative stress

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Type 2 daiabetes mellitus with chronic kidney disease recieving sitagliptin (25-50 mg / day) treatment.

Interventions/Control_2

Type 2 daiabetes mellitus with chronic kidney disease recieving 20mg teneligliptin treatment switched from sitagliptin.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The study subjects were type 2 diabetes mellitus with chronic kidney disease whose hemoglobin A1c (HbA1c) was lower than 10.0% [NGSP] despite treatment with sitagliptin (25-50 mg/day) for at least 4 weeks.All patients had visited the outpatient clinic of Dkkyo Medical University

Key exclusion criteria

Exclusion criteria were (1) type 1 diabetes, (2) severe complications of diabetes, (3) severe liver dysfunction (4) severe infections (5) pregnant or nursing women and those who might be pregnant (6) alcoholism, and (7) any patients whom the investigators judged to be inappropriate for this study.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kunihiro Suzuki

Organization

Dokkyo Medical University

Division name

Endocrinology and Metabolism

Zip code


Address

880, Kitakobayashi, Shimotugagun, Mibu, Tochigi

TEL

0282-87-2150

Email

kuni-s@dokkyomed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Chie Aoki

Organization

Dokkyo Medical University

Division name

Endocrinology and Metabolism

Zip code


Address

880, Kitakobayashi, Shimotugagun, Mibu, Tochigi

TEL

0282-87-2150

Homepage URL


Email

C-aoki@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University

Institute

Department

Personal name



Funding Source

Organization

Endocrinology and Metabolism, Dokkyo Mediacal, University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 20 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://cardiab.biomedcentral.com/articles/10.1186/s12933-016-0396-3

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2014 Year 03 Month 07 Day

Last follow-up date

2015 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 04 Month 20 Day

Last modified on

2016 Year 05 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019934


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name